Ras, PI(3)K and mTOR signalling controls tumour cell growth
The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Abstract
All eukaryotic cells coordinate cell growth with the availability of nutrients in their environment. The mTOR protein kinase has emerged as a critical growth-control node, receiving stimulatory signals from Ras and phosphatidylinositol-3-OH kinase (PI(3)K) downstream from growth factors, as well as nutrient inputs in the form of amino-acid, glucose and oxygen availability. Notably, components of the Ras and PI(3)K signalling pathways are mutated in most human cancers. The preponderance of mutations in these interconnected pathways suggests that the loss of growth-control checkpoints and promotion of cell survival in nutrient-limited conditions may be an obligate event in tumorigenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“many common human cancers have mutations in phosphatidylinositol 3-kinase or upstream signaling pathways (13).”
From Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth (2008) · cites this paper as [13]
In the citing paper
“PI3K signaling may be central to linking the common genetic perturbations of cancer, such as RTK mutations and PTEN loss, with altered metabolic processes, including the “lipogenic phenotype” common to many cancers, including GBM (13, 14, 17, 20).”
From An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent Pathway (2011) · cites this paper as [20]
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787 · cited 8×
“So, the PI(3)K heterodimer is recruited to the membrane to generate local pools of PtdIns(3,4,5)P3.”
BackgroundInfluentialAkt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914 · cited 1×
“AMPK inhibits mTOR at least in part by the direct phosphorylation of tuberin ( Box 3 ), and cells that lack tuberin retain activated mTORC1 under conditions of low glucose as well as hypoxi”
BackgroundRAS Is Regulated by the let-7 MicroRNA Family
Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., Labourier, E., Reinert, K. L., Brown, D., & Slack, F. J. (2005) · Cell · doi:10.1016/j.cell.2005.01.014 · Cited by 3,656 · cited 1×
“In addition to loss of RasGAP function, Ras activity is reported to be elevated through reduced expression of a conserved microRNA (let-7) that targets the 3′ untranslated region of H-ras, N-ras and K-ras messenger RNA”
BackgroundHigh Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104 · cited 1×
“PTEN catalyses removal of the D3 phosphate from PtdIns(3,4,5)P 3 (the reverse of the reaction catalysed by PI(3)K) to limit and ultimately terminate PI(3)K signalling in cell”
BackgroundSarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · cited 1×
“The existence of the S6K-based negative-feedback loop means that prolonged rapamycin treatment will probably lead to enhanced PI(3)K–AKT activation in some tumours, as has been observed in several tumour cell lines grown in culture, and in tissues from patients in clinical trials of rapamycin analogue”
Background
Cited by
Items 701–800 of 1,006
Dobashi, Y., Suzuki, S., Matsubara, H., Kimura, M., Endo, S., & Ooi, A. (2008) · Cancer · doi:10.1002/cncr.23996 · Cited by 53
“Moreover, it may be possible to potentiate anti-EGFR therapy in lung carcinoma by using rapamycin.(12) Treatment with EGFR-tyrosine kinase inhibitors (TKI) alone reportedly suppressed the activity but increase the levels of EGFR expression and subsequently activated its downstream signaling mediators in NSCLC cells.”
BackgroundBiologic rationale and clinical activity of mTOR inhibitors in gynecological cancer
Díaz-Padilla, I., Durán, I., Clarke, B. A., & Oza, A. M. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.02.001 · Cited by 53
Tomitsuka, E., Kita, K., & Esumi, H. (2009) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.85.258 · Cited by 57
Systemic Therapy Options for Unresectable and Metastatic Chordomas
Stacchiotti, S., & Casali, P. G. (2011) · Current Oncology Reports · doi:10.1007/s11912-011-0176-x · Cited by 51
“It is well known that the presence of activated RTKs leads to the activation of secondary transducers belonging to the MAPK or PI3K/AKT pathways, which together activate mammalian target of rapamycin (mTOR), and its effectors, S6K/S6 and 4E-BP1, responsible for harmonizing protein synthesis, and promoting cell growth…”
BackgroundInhibiting kinases in malignant gliomas
Chi, A. S., & Wen, P. Y. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.4.473 · Cited by 54
“Furthermore, it has become clear that intracellular signaling pathways are robust, interconnected networks that possess multiple points of convergence and divergence, compensatory mechanisms and poorly understood feedback mechanisms [107,212].”
BackgroundSarnelli, G., D’Alessandro, A., Iuvone, T., Capoccia, E., Gigli, S., Pesce, M., Seguella, L., Nobile, N., Aprea, G., Maione, F., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156198 · Cited by 53
Lin, J., He, Y., Wang, B., Xun, Z., Chen, S., Zeng, Z., & Ou, Q. (2018) · Clinical & Experimental Immunology · doi:10.1111/cei.13218 · Cited by 51
Wei, Y. Q., Huang, C., Wu, H., & Huang, J. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.30930 · Cited by 53
“The PTEN-PI3K/Akt/mTOR is often considered as a classical autophagic signaling pathway in various cancers [47].”
Netrin-4 Promotes Glioblastoma Cell Proliferation through Integrin β4 Signaling
Hu, Y., Ylivinkka, I., Chen, P., Li, L., Hautaniemi, S., Nyman, T. A., Keski-Oja, J., & Hyytiäinen, M. (2012) · Neoplasia · doi:10.1593/neo.111396 · Cited by 49
Apoptosis initiation of β-ionone in SGC-7901 gastric carcinoma cancer cells via a PI3K-AKT pathway
Liu, Q., Dong, H., Sun, W., Liu, M., Ibla, J. C., Liu, L., Parry, J. W., Han, X., Li, M., & Liu, J. (2012) · Archives of Toxicology · doi:10.1007/s00204-012-0962-8 · Cited by 56
“Annexin V binds to phosphatidylserine externalized on the cell surface in association with apoptosis, and annexin V staining is, therefore, used for the detection of apoptosis at an early stage (Shounan et al. 1998).”
MethodThe mTOR pathway negatively controls ATM by up-regulating miRNAs
Shen, C., & Houghton, P. J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220898110 · Cited by 50
“Second, up-regulated mTOR activity results in unchecked cell survival and proliferation (17, 35).”
BackgroundZhang, X., Wang, Y., Liu, X., Zhao, A., Yang, Z., Kong, F., Sun, L., Yu, Y., & Jiang, L.-P. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109840 · Cited by 51
Longevity Genes: Insights from Calorie Restriction and Genetic Longevity Models
Shimokawa, I., Chiba, T., Yamaza, H., & Komatsu, T. (2008) · Molecules and Cells · doi:10.1016/s1016-8478(23)14018-0 · Cited by 51
“Because a failure to inhibit mTOR results in increased neoplasm (Shaw and Cantley, 2006), CR may suppress neoplastic processes by activating mTOR.”
BackgroundYang, Z., Zhang, L., Ma, A., Liu, L., Li, J., Gu, J., & Liu, Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028405 · Cited by 52
Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review
Huang, Z., Wu, Y., Zhou, X. Y., Qian, J., Zhu, W., Shu, Y., & Liu, P. (2015) · Future Oncology · doi:10.2217/fon.15.70 · Cited by 54
Loehberg, C. R., Strissel, P. L., Dittrich, R., Strick, R., Dittmer, J., Dittmer, A., Fabry, B., Kalender, W. A., Koch, T., Wachter, D. L., et al. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.11.022 · Cited by 54
“Whereas, mTORC1 is known to be a pivotal regulator of cell size and cell cycle control, the question whether the recently discovered mTORC2 complex is involved in these processes remained elusive [3,4].”
BackgroundCombination of Rapamycin and Resveratrol for Treatment of Bladder Cancer
Alayev, A., Salamon, R. S., Schwartz, N. S., Berman, A. Y., Wiener, S. L., & Holz, M. K. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25443 · Cited by 52
“…regulates cell growth, survival, motility, metabolism, and angiogenesis (Sengupta et al., 2010; Alayev and Holz, 2013) and is often hyperactivated in a variety of cancers (Shaw and Cantley, 2006; Liu et al., 2009; Courtney et al., 2010; Bartholomeusz and Gonzalez-Angulo, 2012; Populo et al., 2012).”
BackgroundZhang, Y.-T. Y., Zhu, X., Huang, T., Chen, L., Liu, Y., Li, Q., Song, J., Ma, S., Zhang, K., Yang, B., et al. (2016) · Toxicology Letters · doi:10.1016/j.toxlet.2016.08.010 · Cited by 51
Kang, S. A., O’Neill, D. J., Machl, A. W., Lumpkin, C. J., Galda, S. N., Sengupta, S., Mahoney, S. J., Howell, J. J., Molz, L., Hahm, S., et al. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.05.009 · Cited by 53
The role of FOXOs and autophagy in cancer and metastasis—Implications in therapeutic development
Farhan, M., Silva, M., Li, S., Yan, F., Fang, J., Peng, T., Hu, J., Tsao, M., Little, P. J., & Zheng, W. (2020) · Medicinal Research Reviews · doi:10.1002/med.21695 · Cited by 54
Sudhan, D. R., Guerrero-Zotano, A., Won, H., González Ericsson, P., Servetto, A., Huerta-Rosario, M., Ye, D., Lee, K.-M., Formisano, L., Guo, Y., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.013 · Cited by 49
Phosphorylated 4E‐binding protein 1 (p‐4E‐BP1): a novel prognostic marker in human astrocytomas
Korkolopoulou, P. A., Levidou, G., El-Habr, E. A., Piperi, C., Adamopoulos, C., Samaras, V. D., Boviatsis, E. I., Thymara, I., Trigka, E., Sakellariou, S., et al. (2012) · Histopathology · doi:10.1111/j.1365-2559.2012.04236.x · Cited by 55
“mTOR is mainly, although not solely, activated by AKT, either directly, or indirectly via phosphorylation and inactivation of its inhibitor tuberous sclerosis complex (TSC) 2.(2) Two downstream pathways of mTORC1 involved in the translation machinery are responsible for ribosome recruitment to mRNA: phosphorylation an…”
BackgroundMagnin, S., Viel, E., Baraquin, A., Valmary‐Degano, S., Kantelip, B. M., Prétet, J., Mougin, C., Bigand, M., Girardo, B., Borg, C., et al. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2011.05.010 · Cited by 49
Liu, Z., Antalek, M., Nguyen, L., Li, X., Tian, X., Le, A. T., & Zi, X. (2013) · Nutrition and Cancer · doi:10.1080/01635581.2013.785011 · Cited by 49
The mTOR (Mammalian Target of Rapamycin) Kinase Maintains Integrity of mTOR Complex 2
Chen, C.-H., & Sarbassov, D. D. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.282590 · Cited by 48
Watanabe, M., Sowa, Y., Yogosawa, M., & Sakai, T. (2013) · Cancer Science · doi:10.1111/cas.12139 · Cited by 52
Regulation of the Ras-MAPK and PI3K-mTOR Signalling Pathways by Alternative Splicing in Cancer
Siegfried, Z., Bonomi, S., Ghigna, C., & Karni, R. (2013) · International Journal of Cell Biology · doi:10.1155/2013/568931 · Cited by 53
“Upon RTK activation, both the Ras-MAPK and the PI3KmTOR pathways are activated [16, 17] (Figure 2).”
BackgroundRafiee, P., Binion, D. G., Wellner, M. R., Behmaram, B., Floer, M., Mitton‐Fitzgerald, E., Nie, L., Zhang, Z., & Otterson, M. F. (2010) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00339.2009 · Cited by 49
“PI3K/Akt is the most targeted pathway in human cancers, since its activation leads to cell proliferation and cell survival via mechanisms that are presently not well defined (53).”
BackgroundLee, J.-S., Padmanabhan, A., Shin, J., Zhu, S., Guo, F., Kanki, J. P., Epstein, J. A., & Look, A. T. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq395 · Cited by 52
“To further investigate the effect of nf1 deficiency on Ras signaling during OPC development, we examined two principal pathways downstream of activated Ras by evaluating the status of phosphorylated ERK and phosphorylated S6 to assess the Raf/ERK and PI3K/Akt/mTOR pathways, respectively (31).”
Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics
Josephs, D. H., & Sarker, D. (2015) · Translational Oncogenomics · doi:10.4137/tog.s30529 · Cited by 55
“Glucose metabolism measured by [(1)(8)F]fluorodeoxyglucose positron emission tomography is independent of PTEN/AKT status in human colon carcinoma cells.”
MethodLiu, G., Song, Y., Cui, L., Zhaoxia, W., & Lu, X. (2015) · Europe PMC (PubMed Central) · Cited by 53
Zhang, H., Chen, R., Sun, G., Yang, L., Zhu, Y., Xu, X., & Sun, X. (2018) · Phytomedicine · doi:10.1016/j.phymed.2018.01.004 · Cited by 49
The potential of breath analysis to improve outcome for patients with lung cancer
Antoniou, S., Gaude, E., Ruparel, M., van der Schee, M. P., Janes, S. M., & Rintoul, R. C. (2019) · Journal of Breath Research · doi:10.1088/1752-7163/ab0bee · Cited by 51
Meng, X., Zhang, C., Guo, Y., Han, Y., Wang, C., Chu, H., Kong, L., & Ma, H. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/8787156 · Cited by 52
“Once AKT is activated, the biological response of AKT that controls apoptosis is simultaneously activated [64].”
BackgroundMacciò, A., Sanna, E., Neri, M., Oppi, S., & Madeddu, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062890 · Cited by 55
Regulation of Immune Responses and Hematopoiesis by the Rap1 Signal
Minato, N., Kometani, K., & Hattori, M. (2007) · Advances in immunology · doi:10.1016/s0065-2776(06)93006-5 · Cited by 51
Jiang, R., & Lönnerdal, B. L. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2011.10.002 · Cited by 55
Targeting multiple kinases in glioblastoma multiforme
Sathornsumetee, S., & Reardon, D. A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802692603 · Cited by 51
“Prenylation is the rate-limiting step in RAS maturation; therefore, several farnesyltransferase inhibitors (FTIs) have undergone clinical evaluation as a RAS targeted therapy.”
BackgroundInfluentialChen, J., Wang, F., & Chen, W. (2014) · Molecular Biology Reports · doi:10.1007/s11033-014-3329-9 · Cited by 50
“Phosphatidylinositol 3-kinase (PI3 K)-Akt signaling pathway is a well-characterized anti-apoptotic cascade in human cancers, since its activation leads to cell proliferation and cell survival [57].”
BackgroundCommon Oncogenic Mutations Are Infrequent in Oral Squamous Cell Carcinoma of Asian Origin
Zanaruddin, S. N. S., Yee, P. S., Hor, S. Y., Kong, Y. H., Ghani, W. M. N., Mustafa, W. M. W., Zain, R. B., Prime, S. S., Rahman, Z. A. A., & Cheong, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080229 · Cited by 49
“Deregulation of HRAS is known to activate two major signaling pathways, namely, PI3K/AKT and MAPK [35,36].”
BackgroundTranslation initiation: a critical signalling node in cancer
Robert, F., & Pelletier, J. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903241625 · Cited by 48
“They oscillate from the inactivated form (Ras•GDP) to the activated form (Ras•GTP) upon stimulation and their activity is modulated by GTPase-activating proteins [46].”
BackgroundInfluentialInsulin sparing action of Adenovirus 36 and its E4orf1 protein
Dhurandhar, N. V. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.09.006 · Cited by 49
Dai, B., Kong, Y. Y., Ye, D. W., Ma, C.-G., Zhou, X., & Yao, X. (2009) · British Journal of Urology · doi:10.1111/j.1464-410x.2009.08538.x · Cited by 48
McCullar, B., Pandey, M. K., Yaghmour, G., Hare, F., Patel, K., Stein, M. K., Feldman, R. A., Chandler, J. C., & Martin, M. G. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3867-z · Cited by 50
An extended Myc network contributes to glucose homeostasis in cancer and diabetes
Christopher, W. P. (2011) · Frontiers in bioscience · doi:10.2741/3848 · Cited by 53
Zhang, L., Luo, X., & Qiao, S. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01757-y · Cited by 48
Zhang, H., Zhang, P., & Sun, H. (2009) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2009.04.035 · Cited by 53
RNA-binding proteins as a point of convergence of the PI3K and p38 MAPK pathways
Venigalla, R. K., & Turner, M. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00398 · Cited by 51
“In addition to SYK, the Erk pathway can also activate mTOR (Shaw and Cantley, 2006).”
BackgroundMutations in Critical Domains Confer the Human mTOR Gene Strong Tumorigenicity*
Murugan, A. K., Alzahrani, A., & Xing, M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.399485 · Cited by 45
“driven deregulation of upstream signaling, particularly that of the PI3K/Akt and MAP kinase pathways (3, 9, 10).”
BackgroundAlqurashi, N., Hashimi, S. M., & Wei, M. Q. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14023874 · Cited by 51
“The P13K-Akt-ERK pathways upstream of mTORC1 are activated downstream of both receptor tyrosine kinases (RTKs) and Ras [78,79].”
The tuberous sclerosis complex: balancing proliferation and survival
Tomasoni, R., & Mondino, A. (2011) · Biochemical Society Transactions · doi:10.1042/bst0390466 · Cited by 46
Wu, K., Yang, L., Chen, J., Zhao, H., Wang, J., Xu, S., & Huang, Z.-H. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.05.056 · Cited by 49
“PI3K generates 30-phosphorylated phosphoinositides as intracellular second messengers and is a hallmark of many signaling pathways [21]; it controls multiple cellular responses, including proliferation, growth and invasion.”
BackgroundLiu, Z., Gan, L., Liu, G., Chen, Y., Wu, T., Feng, F., & Sun, C. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m063537 · Cited by 47
The Roles of Protein Tyrosine Phosphatases in Hepatocellular Carcinoma
Huang, Y., Zhang, Y., Ge, L., Lin, Y., & Kwok, H. F. (2018) · Cancers · doi:10.3390/cancers10030082 · Cited by 51
“In addition, over-activation of phosphatidylinositol-3-OH kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling pathway leads to enhanced proliferation and metastasis in HCC [3,4].”
BackgroundmiR-183-5p functions as a tumor suppressor in lung cancer through PIK3CA inhibition
Meng, F., & Zhang, L. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.12.003 · Cited by 47
Myeloid cell-derived LL-37 promotes lung cancer growth by activating Wnt/β-catenin signaling
Ji, P., Zhou, Y., Yang, Y., Wu, J., Zhou, H., Quan, W., Sun, J., Yao, Y., Shang, A., Gu, C., et al. (2019) · Theranostics · doi:10.7150/thno.30726 · Cited by 50
“targets, including forkhead box O3 and proline-rich Akt substrate of 40 kDa [30, 31].”
BackgroundJin, J., Shi, Y., Zhang, S., & Yang, S. (2019) · Acta Oncologica · doi:10.1080/0284186x.2019.1664764 · Cited by 47
de Castro, L. F., Ovejero, D., & Boyce, A. M. (2020) · European Journal of Endocrinology · doi:10.1530/eje-19-0969 · Cited by 47
Lacher, M. D., Pincheira, R., Zhu, Z., Camoretti-Mercado, B., Matli, M. R., Warren, R. S., & Castro, A. F. (2010) · Oncogene · doi:10.1038/onc.2010.393 · Cited by 48
Adipose tissue dysfunction and its effects on tumor metabolism
Diedrich, J. D., Chkourko, H., & Podgorski, I. (2015) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2014-0045 · Cited by 54
O'Shea, J. M., & Ayer, D. E. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014258 · Cited by 47
“…sp ec ti ve si n m ed ic in e. o rg preponderance of PI3K and Ras activation in cancer and their established function in driving aerobic glycolysis (Shaw and Cantley 2006), we propose that their suppression of the MondoATXNIP circuit may be a general feature of the metabolic phenotype observed in…”
BackgroundTranslational control by oncogenic signaling pathways
Gao, B., & Roux, P. P. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.11.006 · Cited by 54
A zebrafish model of chordoma initiated by notochord-driven expression of HRASV12
Burger, A., Vasilyev, A., Tomar, R., Selig, M. K., Nielsen, G. P., Peterson, R. T., Drummond, I. A. S., & Haber, D. A. (2013) · Disease Models & Mechanisms · doi:10.1242/dmm.013128 · Cited by 46
“This article is part of a Special Issue, Spotlight on Zebrafish: Translational Impact.”
EGFR inhibitors and autophagy in cancer treatment
Cui, J., Hu, Y., Feng, X.-M., Tian, T., Guo, Y., Ma, J., Nan, K., & Zhang, H. (2014) · Tumor Biology · doi:10.1007/s13277-014-2660-z · Cited by 50
Kim, K. W., Myers, C. J., Jung, D. K., & Lu, B. (2014) · Genes & Cancer · doi:10.18632/genesandcancer.27 · Cited by 46
“Both PTEN loss [9] and PIKC3A gene copy amplification have been reported in NSCLC [10-11].”
BackgroundKRAS Engages AGO2 to Enhance Cellular Transformation
Shankar, S., Pitchiaya, S., Malik, R., Kothari, V., Hosono, Y., Yocum, A. K., Gundlapalli, H., White, Y., Firestone, A., Cao, X., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.01.034 · Cited by 46
“Constitutively elevated levels of Ras-GTP aberrantly activate downstream effector pathways that promote neoplastic transformation (Karnoub and Weinberg, 2008; Shaw and Cantley, 2006; Trahey and McCormick, 1987).”
Regulation of CHK1 by mTOR contributes to the evasion of DNA damage barrier of cancer cells
Zhou, X., Liu, W., Hu, X., Dorrance, A. M., Garzon, R., Houghton, P. J., & Shen, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-01729-w · Cited by 49
Fisetin and 5‐fluorouracil: Effective combination for PIK3CA‐mutant colorectal cancer
Khan, N., Jajeh, F., Eberhardt, E. L., Miller, D. D., Albrecht, D. M., Doorn, R. R. V., Hruby, M. D., Maresh, M. E., Clipson, L. J., Mukhtar, H., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32367 · Cited by 48
Wang, Y., Yuan, Y., Gao, Y., Li, X., Tian, F., Liu, F., Du, R., Li, P., Wang, F., Xu, S., et al. (2019) · Brain and Development · doi:10.1016/j.braindev.2019.04.010 · Cited by 48
The Biology of the Nuclear Envelope and Its Implications in Cancer Biology
Alvarado-Kristensson, M., & Rosselló, C. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102586 · Cited by 49
Circulating Biomarkers in Malignant Melanoma
Alegre, E., Sammamed, M., Landazuri, S. F., Zubiri, L., & González, Á. (2015) · Advances in clinical chemistry · doi:10.1016/bs.acc.2014.12.002 · Cited by 55
Hong, S., Luo, X., Montalbano, J., Jin, W., Shi, J., Sheikh, M. S., & Huang, Y. K. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0278 · Cited by 46
“Ras proteins are major molecular switches for the phosphoinositide 3-kinase (PI3K) signaling pathway and the extracellular signal-regulated kinase (ERK) signaling pathways (4).”
BackgroundInfluentialSharp, Z. D., & Strong, R. (2010) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glp212 · Cited by 46
“Manning BD, Logsdon MN, Lipovsky AI, Abbott D, Kwiatkowski DJ, Cantley LC. Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2.”
BackgroundInfluentialExploring the mTOR Signalling Pathway and Its Inhibitory Scope in Cancer
Mir, S. A., Dar, A., Alshehri, S. A., Wahab, S., Hamid, L., Almoyad, M. A. A., Ali, T., & Bader, G. N. (2023) · Pharmaceuticals · doi:10.3390/ph16071004 · Cited by 53
Coiffier, B., & Ribrag, V. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190903207548 · Cited by 46
Akt activation protects pancreatic beta cells from AMPK-mediated death through stimulation of mTOR
Cai, Y., Wang, Q., Ling, Z., PIPELEERS, D. G., McDermott, P. J., Pende, M., Heimberg, H., & de Casteele, M. V. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.02.019 · Cited by 50
Variants on the promoter region of PTEN affect breast cancer progression and patient survival
Heikkinen, T., Greco, D., Pelttari, L. M., Tommiska, J., Vahteristo, P., Heikkilä, P., BLOMQVIST, C. P., Aittomäki, K., & Nevanlinna, H. A. (2011) · Breast Cancer Research · doi:10.1186/bcr3076 · Cited by 47
“Alterations in this pathway are among the most common changes in human carcinogenesis [21].”
BackgroundAmornphimoltham, P., Patel, V., Leelahavanichkul, K., Abraham, R. T., & Gutkind, J. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-1756 · Cited by 48
“In this regard, emerging evidence suggests that the aberrant activity of the Aktmammalian target of rapamycin (mTOR) signaling pathway is a frequent event in some of the most prevalent human cancers (1, 2).”
BackgroundSquillace, R. M., Miller, D., Cookson, M. M., Wardwell, S., Moran, L. E., Clapham, D., Wang, F., Clackson, T., & Rivera, V. M. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0273 · Cited by 45
“mTOR is a downstream effector of PI3K/AKT pathway signaling, aberrant activation of which is linked to critical aspects of tumor cell biology, including resistance to apoptosis, increased cell proliferation and regulation of metabolism (6-8).”
BackgroundBlando, J. M., Portis, M. J., Benavides, F. J., Alexander, A., Mills, G. B., Dave, B., Conti, C. J., Kim, J., & Walker, C. L. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080055 · Cited by 49
PRAS40 Regulates Protein Synthesis and Cell Cycle in C2C12 Myoblasts
Kazi, A. A., & Lang, C. H. (2010) · Molecular Medicine · doi:10.2119/molmed.2009.00168 · Cited by 49
Tsubaki, M., Fujiwara, D., Takeda, T., Kino, T., Tomonari, Y., Itoh, T., Imano, M., Satou, T., Sakaguchi, K., & Nishida, S. (2017) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12690 · Cited by 50
“Oncogenic Ras induces the activation of mTOR in tumor cell growth.(31) In addition, oncogenic KRas, which is required for anchoring GGPP, activates the PI3K/mTOR pathway in non-small cell lung cancer.”
BackgroundPKM2 Knockdown Induces Autophagic Cell Death via AKT/mTOR Pathway in Human Prostate Cancer Cells
Dey, P. K., Kundu, A. B., Sachan, R., Park, J. H., Ahn, M. Y., Yoon, K., Lee, J., Kim, N. D., Kim, I. S., Lee, B. M., et al. (2019) · Cellular Physiology and Biochemistry · doi:10.33594/000000107 · Cited by 51
Clătici, V. G., Voicu, C., Voaideṣ, C., Roșeanu, A., Icriverzi, M., & Jurcoane, Ș. (2018) · Europe PMC (PubMed Central) · doi:10.26574/maedica.2018.13.4.273 · Cited by 51
Leung, E. Y., Askarian-Amiri, M., Finlay, G. J., Rewcastle, G. W., & Baguley, B. C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131400 · Cited by 47
“Due to a negative feedback loop [33], inhibition of mTORC1 can induce AKT S473 phosphorylation in a subset of cancer cell lines and patient tumors [34–36], and therefore activation of AKT S473 might attenuate tumor responses [33,37].”
BackgroundRaufman, J., Shant, J., Guo, C. Y., Roy, S. K., & Cheng, K. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21332 · Cited by 47
“In hematopoietic and neuronal cells inactivation of GSK by Akt-mediated phosphorylation also regulates apoptosis (Maurer et al., 2006; Shaw and Cantley, 2006).”
BackgroundSasabe, E., Yang, Z., Ohno, S., & Yamamoto, T. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.02.013 · Cited by 50
Dogan, S., Johannsen, A. C., Grande, J. P., & Cleary, M. P. (2011) · Nutrition and Cancer · doi:10.1080/01635581.2011.535968 · Cited by 45
Tandutinib Inhibits the Akt/mTOR Signaling Pathway to Inhibit Colon Cancer Growth
Ponnurangam, S., Standing, D., Rangarajan, P., & Subramaniam, D. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0907 · Cited by 45
Rafiee, P., Stein, D. J., Nelson, V. M., Otterson, M. F., Shaker, R., & Binion, D. G. (2009) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00385.2009 · Cited by 46
Miyake, N., Chikumi, H., Takata, M., Nakamoto, M., Igishi, T., & Shimizu, E. (2012) · Oncology Reports · doi:10.3892/or.2012.1855 · Cited by 47
“Moreover, the activation of the PI3K/AKT pathway confers resistance to many types of cancer therapy and is a negative prognostic factor for different tumor types (4-6).”
The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma
Li, T., Li, H., Wang, Y., Harvard, C., Tan, J., Au, A., Xu, Z., Jablons, D. M., & You, L. (2011) · The Journal of Pathology · doi:10.1002/path.2829 · Cited by 48
Hollebecque, A., Decaens, T., Boleslawski, E., Mathurin, P., Duvoux, C., Pruvot, F., & Dharancy, S. (2009) · Gastroentérologie Clinique et Biologique · doi:10.1016/j.gcb.2009.02.036 · Cited by 44
Villarreal-Garza, C. M., Cortés, J., André, F., & Verma, S. (2012) · Annals of Oncology · doi:10.1093/annonc/mds075 · Cited by 44
“Two key regulatory loops have been described that may limit the effectiveness of drugs that have been developed to target mTOR in cancer [32].”
BackgroundJérusalem, G., Rorive, A., & Collignon, J. (2014) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s38679 · Cited by 48
“Pathway hyperactivation has been linked to cancer pathogenesis, progression, and treatment resistance.(1) mTOR is a serine-threonine kinase which plays a key role in cell regulation, including responses to multiple stimuli such as amino acid availability, energy and oxygen stresses, and growth factor receptor signalin…”
Sestrin 2 suppresses cells proliferation through AMPK/mTORC1 pathway activation in colorectal cancer
Wei, J., Fang, M., Fu, Z.-X., Zhang, S., Guo, J., Wang, R., Lv, Z., & Xiong, Y.-F. (2017) · Oncotarget · doi:10.18632/oncotarget.17595 · Cited by 44
Evolving role of Sorafenib in the management of hepatocellular carcinoma
Ziogas, I. A., & Tsoulfas, G. (2017) · World Journal of Clinical Oncology · doi:10.5306/wjco.v8.i3.203 · Cited by 51
Association between AKT/mTOR signalling pathway and malignancy grade of human gliomas
Li, X., Zhang, L.-Q., Zhang, X.-G., Li, X., Ren, Y., Ma, X.-Y., Li, X., & Wang, L. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0424-1 · Cited by 44
“The mammalian target of rapamycin (mTOR), a 250-kDa protein, regulates multiple cell growth and cellular functions by controlling mRNA translation, ribosome biogenesis, autophagy, and metabolism [ 1 , 2]. Evidence is emerging that mTOR is involved in the pathogenesis of several human cancers [3], and inhibition of mTO…”
BackgroundBuitrago‐Molina, L. E., Pothiraju, D., Lamlé, J., Marhenke, S., Kossatz-Boehlert, U., Breuhahn, K., Manns, M. P., Malek, N. P., & Vogel, A. (2009) · Hepatology · doi:10.1002/hep.23014 · Cited by 48
Are we on the brink of nonsurgical treatment for ameloblastoma?
Sauk, J. J., Nikitakis, N. G., & Scheper, M. A. (2010) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1016/j.tripleo.2010.01.024 · Cited by 49
Metadata
- Authors
- Shaw, R. J., & Cantley, L. C.
- Affiliations
- Salk Institute for Biological Studies (US)
- Beth Israel Deaconess Medical Center (US)
- Venue
- Nature
- Published
- 2006-05
- Volume
- 441
- Issue
- 7092
- Pages
- 424-430
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2144323242
- Cited by
- 2,019
- References
- 86
- Citations by year
- 2026: 26 · 2025: 40 · 2024: 48 · 2023: 68 · 2022: 68 · 2021: 77 · 2020: 91 · 2019: 74 · 2018: 95 · 2017: 99 · 2016: 109 · 2015: 146 · 2014: 119 · 2013: 153 · 2012: 143
- FWCI
- 9.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM041890)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- Ras signaling, PI3K signaling, mTOR signaling, tumour cell growth, nutrient sensing, amino acids, glucose, oxygen availability, cancer mutations, carcinogenesis, cell survival
- MeSH terms
- Animals, Humans, Neoplasms, Protein Kinases, Signal Transduction, ras Proteins, Phosphatidylinositol 3-Kinases, Cell Growth Processes, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.